Imunon, Inc. (IMNN) Stock Score, Valuation & Financial Research
Imunon, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for IMNN
Imunon, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.29. These figures are a research snapshot, not a buy or sell recommendation.
What Imunon, Inc. does
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
Imunon is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of its proprietary DNA-based immunotherapy and vaccine platforms.
Products and services
- The company is developing IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, and IMNN-101, a COVID-19 booster vaccine candidate, utilizing its proprietary non-viral synthetic delivery platform.
Suppliers, materials and equipment
- Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party vendors for clinical trial management, data collection, and the manufacturing of clinical trial materials. Specific supplier names are not disclosed. Source
Business strengths to evaluate
- Proprietary non-viral DNA and mRNA delivery technology platform Source
- Advanced clinical development status of lead candidate IMNN-001 Source
Business risks and research considerations
- Recurring losses from operations and significant accumulated deficit Source
- Substantial doubt regarding the company's ability to continue as a going concern Source
- Dependence on successful clinical trial outcomes and regulatory approvals Source
Sources: Company research source
Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
IMNN financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 1.29
- Market capitalization:
- 5.42M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -14.72M
- Free cash flow:
- USD -14.18M
- Cash:
- USD 6.86M
- Total debt:
- USD 7.85M
- EPS:
- USD -4.53
What stands out
- Free cash flow is USD -14.18M, negative for the stored period.
- The balance sheet shows USD 6.86M of cash versus USD 7.85M of total debt, with debt exceeding cash on these two reported measures.
- The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Debt exceeds cash by USD 980.91K using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for IMNN
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can IMNN fund negative free cash flow using its current cash position before it may need more debt or new shares?
- Does IMNN's balance between cash and debt leave enough flexibility if business conditions weaken?
- What specifically needs to improve for IMNN to reach sustainable profitability?
- What does the current fundamental change risk warning mean for the reliability or interpretation of IMNN's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 73% of the scoring inputs required for this public page are currently available.
How to research IMNN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.